Sign in to continue:

Friday, April 10th, 2026

TPG Inc. Files Form 8-K Announcing Listing of Class A Common Stock and 6.950% Subordinated Notes on NASDAQ

TPG Inc. Announces Appointment of Admiral William H. McRaven to Board of Directors

FORT WORTH, TX – April 9, 2026 – TPG Inc. (Nasdaq: TPG, TPGXL), a leading global alternative asset management firm, has announced a significant change to its Board of Directors with the appointment of Admiral William H. McRaven (Retired) as a new director, effective immediately. This development was disclosed in a Form 8-K filing with the U.S. Securities and Exchange Commission (SEC), dated April 8, 2026.

Key Highlights from the SEC Filing

  • New Director Appointment: Admiral William H. McRaven, a highly distinguished retired U.S. Navy Admiral and former Commander of U.S. Special Operations Command, has joined the TPG Inc. Board of Directors.
  • Strategic Implications: Admiral McRaven brings decades of leadership, strategic planning, and operational expertise to TPG, which could positively influence the company’s governance, risk management, and long-term strategy.
  • Corporate Governance Enhancement: The addition of Admiral McRaven is intended to enhance the depth and breadth of experience on the Board and reflects TPG’s commitment to world-class governance and oversight.
  • Disclosure Compliance: The information regarding Admiral McRaven’s appointment was furnished under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits) pursuant to SEC requirements.

Potential Impact for Shareholders

  • Price-Sensitive News: The addition of a high-profile director such as Admiral McRaven is notable and may be interpreted positively by investors, as it could strengthen TPG’s leadership and strategic vision.
  • Enhanced Reputation and Network: Admiral McRaven’s extensive experience in national security and leadership at the highest levels of government and military could open new opportunities and partnerships for TPG, potentially supporting future growth and innovation.
  • Market Reaction: Such leadership appointments are often viewed favorably by the market, as they signal stability, credibility, and a forward-looking approach to governance. Investors may see this as a move to further solidify TPG’s standing as a premier investment manager.
  • No Other Material Events Disclosed: The Form 8-K did not disclose any other resignations of directors, changes in key executives, or material business events beyond the Board appointment.

Details on TPG’s Securities

  • TPG’s Class A Common Stock is listed on the Nasdaq Global Select Market under the symbol TPG.
  • TPG’s 6.950% Subordinated Notes due 2064 are listed on the Nasdaq Global Market under the symbol TPGXL.

Contact Information

Shareholders: Gary Stein & Evanny Huang ([email protected])
Media: Luke Barrett & Ethan Cherry ([email protected])

Conclusion

The appointment of Admiral William H. McRaven as a director marks a noteworthy development for TPG Inc. His leadership experience and reputation are expected to enhance the company’s strategic direction and governance. Shareholders and potential investors should monitor market reaction to this announcement, as the addition of such a distinguished figure may influence investor sentiment and potentially affect TPG’s share value.


Disclaimer: This article summarizes information publicly disclosed by TPG Inc. in its Form 8-K filing dated April 8, 2026. It is provided for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisor before making investment decisions. The information is believed to be accurate as of the date of publication but is subject to change without notice.

View TPG Inc. Historical chart here



Summit Therapeutics Inc. 2025 Annual Report: Business Overview, Risk Factors, Clinical Pipeline, and Regulatory Insights

Summit Therapeutics Inc. 2025 Annual Report: Key Investor Hi...

Smart Sand, Inc. Files Form 8-K with SEC Detailing Company Information and Contact Details (April 2026)

Smart Sand, Inc. Declares Special Dividend: What Investors N...

EyePoint Pharmaceuticals Reports Q4 and Full-Year 2025 Results, Advances DURAVYU Phase 3 Trials for Wet AMD and DME

EyePoint Pharmaceuticals Reports Q4 and Full-Year 2025 Resul...

   Ad